Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals Incorporated (VRTX) is attracting investor attention: Here is what you should know
Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
An update from Vertex Minerals Ltd. ( ($AU:VTX) ) is now available. Vertex Minerals director Tully Richards has increased his holding in the ...
Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...
Vertex Pharmaceuticals (VRTX) closed at $453.74 in the latest trading session, marking a -1.31% move from the prior day. This ...
This stock is a great choice for cautious and aggressive investors.
Now, it’s worth noting Stock Advisor’s total average return is 966 % — a market-crushing outperformance compared to 194% for ...
EQUITIES on the Dar es Salaam Stock Exchange rose modestly Wednesday, with banks extending recent gains as investors focused ...
Leerink raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption ...
Utah Gov. Spencer Cox says anchoring men in family, faith and community ‘critically important’ for Utah, nation ...
Amazon ( AMZN +0.26%) continues to underscore the strength of its business and deliver fantastic growth for long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback